MetaTOC stay on top of your field, easily

Changing trends in androgen deprivation therapy prescribing for prostate cancer in England, 2015–2024

, , , , , , , , , , ,

Journal of Oncology Pharmacy Practice

Published online on

Abstract

Journal of Oncology Pharmacy Practice, Ahead of Print.
IntroductionGonadotropin-releasing hormone (GnRH) agonists are the most commonly used form of androgen deprivation therapy (ADT) for advanced prostate cancer, often prescribed with radiotherapy or chemotherapy. This study examined national trends in the ...